Hepatocellular Carcinoma - Pipeline Review, H2 2017

Date: November 30, 2017
Pages: 1120
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HDDA6A0D3B4EN
Leaflet:

Download PDF Leaflet

Hepatocellular Carcinoma - Pipeline Review, H2 2017
Hepatocellular Carcinoma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 79, 51, 3, 72, 10 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 11, 7, 1, 26 and 2 molecules, respectively.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Hepatocellular Carcinoma - Overview
Hepatocellular Carcinoma - Therapeutics Development
Hepatocellular Carcinoma - Therapeutics Assessment
Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
Hepatocellular Carcinoma - Drug Profiles
Hepatocellular Carcinoma - Dormant Projects 1068
Hepatocellular Carcinoma - Discontinued Products 1076
Hepatocellular Carcinoma - Product Development Milestones 1079
Appendix 1092

LIST OF TABLES

Number of Products under Development for Hepatocellular Carcinoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Abivax SA, H2 2017
Hepatocellular Carcinoma - Pipeline by ACEA Biosciences Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H2 2017
Hepatocellular Carcinoma - Pipeline by Amgen Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by ArQule Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H2 2017
Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2017
Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Co, H2 2017
Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2017
Hepatocellular Carcinoma - Pipeline by Celgene Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Cellivery Therapeutics Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Celsion Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Conatus Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Curevac AG, H2 2017
Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2017
Hepatocellular Carcinoma - Pipeline by eFFECTOR Therapeutics Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Eiger BioPharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Eli Lilly and Co, H2 2017
Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Epizyme Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H2 2017
Hepatocellular Carcinoma - Pipeline by Eureka Therapeutics Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H2 2017
Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H2 2017
Hepatocellular Carcinoma - Pipeline by Genelux Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Genentech Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2017
Hepatocellular Carcinoma - Pipeline by Genosco Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2017
Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Green Cross Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H2 2017
Hepatocellular Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H2 2017
Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2017
Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Immunovative Therapies Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by In-Cell-Art SAS, H2 2017
Hepatocellular Carcinoma - Pipeline by Incyte Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by InteRNA Technologies BV, H2 2017
Hepatocellular Carcinoma - Pipeline by Ipsen SA, H2 2017
Hepatocellular Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H2 2017
Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H2 2017
Hepatocellular Carcinoma - Pipeline by Kite Pharma Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Komipharm International Co Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Kowa Co Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by MaxCyte Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by MedImmune LLC, H2 2017
Hepatocellular Carcinoma - Pipeline by Medivir AB, H2 2017
Hepatocellular Carcinoma - Pipeline by Merck & Co Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2017
Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Midatech Pharma Plc, H2 2017
Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Mina Therapeutics Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Molecular Templates Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by MTG Biotherapeutics Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by MultiCell Technologies Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by NeuroVive Pharmaceutical AB, H2 2017
Hepatocellular Carcinoma - Pipeline by NormOxys Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2017
Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Omeros Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Oneness Biotech Co Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by OSE Immunotherapeutics, H2 2017
Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by PepVax Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Peregrine Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Pfizer Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Pharma Mar SA, H2 2017
Hepatocellular Carcinoma - Pipeline by PharmAbcine Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corp, H2 2017
Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH (Inactive), H2 2017
Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Q BioMed Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Samumed LLC, H2 2017
Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2017
Hepatocellular Carcinoma - Pipeline by Simcere Pharmaceutical Group, H2 2017
Hepatocellular Carcinoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by TC BioPharm Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by tella Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Tiziana Life Sciences Plc, H2 2017
Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Tumorend LLC, H2 2017
Hepatocellular Carcinoma - Pipeline by Twoxar Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by UbiVac LLC, H2 2017
Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2017
Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by VG Life Sciences Inc, H2 2017
Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics LLC, H2 2017
Hepatocellular Carcinoma - Pipeline by Xspray Pharma AB, H2 2017
Hepatocellular Carcinoma - Pipeline by Yooyoung Pharm Co Ltd, H2 2017
Hepatocellular Carcinoma - Pipeline by Zhejiang Conba Pharmaceutical Co Ltd, H2 2017
Hepatocellular Carcinoma - Dormant Projects, H2 2017 1095
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.1), H2 2017 1096
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.2), H2 2017 1097
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.3), H2 2017 1098
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.4), H2 2017 1099
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.5), H2 2017 1100
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.6), H2 2017 1101
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.7), H2 2017 1102
Hepatocellular Carcinoma - Discontinued Products, H2 2017 1103
Hepatocellular Carcinoma - Discontinued Products, H2 2017 (Contd.1), H2 2017 1104
Hepatocellular Carcinoma - Discontinued Products, H2 2017 (Contd.2), H2 2017 1105

LIST OF FIGURES

Number of Products under Development for Hepatocellular Carcinoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
Abivax SA
ACEA Biosciences Inc
Adaptimmune Therapeutics Plc
Advenchen Laboratories LLC
Amgen Inc
AndroScience Corp
ArQule Inc
Array BioPharma Inc
Aslan Pharmaceuticals Pte Ltd
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
Bio-Cancer Treatment International Ltd
Biomics Biotechnologies Co Ltd
Bioneer Corp
Blueprint Medicines Corp
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Can-Fite BioPharma Ltd
CASI Pharmaceuticals Inc
CBT Pharmaceuticals Inc
CCRP Therapeutics GmbH
Celgene Corp
Celldex Therapeutics Inc
Cellivery Therapeutics Inc
Celsion Corp
China Medical System Holdings Ltd
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co Ltd
Conatus Pharmaceuticals Inc
Curevac AG
Delcath Systems Inc
Double Bond Pharmaceutical International AB
eFFECTOR Therapeutics Inc
Eiger BioPharmaceuticals Inc
Eisai Co Ltd
Eli Lilly and Co
Epeius Biotechnologies Corp
Epizyme Inc
eTheRNA Immunotherapies NV
Eureka Therapeutics Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Galaxy Biotech LLC
Genelux Corp
Genentech Inc
Genoscience Pharma
Genosco Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Golden Biotechnology Corp
Green Cross Cell Corp
Green Cross Corp
H3 Biomedicine Inc
Horizon Pharma Plc
Immatics Biotechnologies GmbH
Immunicum AB
Immunitor Inc
Immunomedics Inc
Immunovative Therapies Ltd
In-Cell-Art SAS
Incyte Corp
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
InteRNA Technologies BV
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KAHR medical Ltd
Karcinolys SAS
Kite Pharma Inc
Komipharm International Co Ltd
Kowa Co Ltd
Ligand Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
MaxCyte Inc
MedImmune LLC
Medivir AB
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Midatech Pharma Plc
Millennium Pharmaceuticals Inc
Mina Therapeutics Ltd
Molecular Templates Inc
MTG Biotherapeutics Inc
MultiCell Technologies Inc
NeuroVive Pharmaceutical AB
NormOxys Inc
Novartis AG
NovaTarg Therapeutics Inc
Nymox Pharmaceutical Corp
Omeros Corp
Oncolys BioPharma Inc
Oneness Biotech Co Ltd
Ono Pharmaceutical Co Ltd
OSE Immunotherapeutics
Panacea Pharmaceuticals Inc
PepVax Inc
Peregrine Pharmaceuticals Inc
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
PharmaEssentia Corp
Provecs Medical GmbH (Inactive)
Provectus Biopharmaceuticals Inc
Q BioMed Inc
RedHill Biopharma Ltd
Regulus Therapeutics Inc
Samumed LLC
Saronic Biotechnology Inc
Shenogen Pharma Group Ltd
Sillajen Biotherapeutics
Simcere Pharmaceutical Group
Sun Pharma Advanced Research Company Ltd
Taiwan Liposome Company Ltd
Takeda Pharmaceutical Co Ltd
TC BioPharm Ltd
tella Inc
Tessa Therapeutics Pte Ltd
Therapure Biopharma Inc
Tiziana Life Sciences Plc
TRACON Pharmaceuticals Inc
Tumorend LLC
Twoxar Inc
UbiVac LLC
VasGene Therapeutics Inc
Vaxon Biotech
Verlyx Pharma Inc
VG Life Sciences Inc
Vicus Therapeutics LLC
Xspray Pharma AB
Yooyoung Pharm Co Ltd
Zhejiang Conba Pharmaceutical Co Ltd
Skip to top


Renal Cell Carcinoma - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 793 pages

Ask Your Question

Hepatocellular Carcinoma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: